NO20064388L - Kaseinavledede peptider og terapeutiske anvendelser derav - Google Patents

Kaseinavledede peptider og terapeutiske anvendelser derav

Info

Publication number
NO20064388L
NO20064388L NO20064388A NO20064388A NO20064388L NO 20064388 L NO20064388 L NO 20064388L NO 20064388 A NO20064388 A NO 20064388A NO 20064388 A NO20064388 A NO 20064388A NO 20064388 L NO20064388 L NO 20064388L
Authority
NO
Norway
Prior art keywords
casein
derived peptides
therapeutic uses
derived
peptides
Prior art date
Application number
NO20064388A
Other languages
English (en)
Inventor
Zvi Sidelman
Original Assignee
Peptera Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptera Pharmaceuticals Ltd filed Critical Peptera Pharmaceuticals Ltd
Publication of NO20064388L publication Critical patent/NO20064388L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732—Casein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Biologisk aktive peptider som er avledet fra eller er tilsvarende til sekvensene til (S1- eller (S2, (- eller ?-kaseinfraksjoner av melkekasein. Disse peptidene er i stand til immumnodulering og andre terapeutiske aktiviteter inkludert, men ikke begrenset til, stimulering og fremming av immunrespons, beskyttelse mot viral infeksjon, normalisering av serumkolesterolnivåer og stimulering av hematopoiesis. De kaseinavledede peptidene er ikke-toksiske og kan bli benyttet for å behandle og forhindre immunpatologier, diabetes, hyperkolesterolemia, hematologiske forstyrrelser og viral-relaterte sykdommer.
NO20064388A 2004-03-01 2006-09-28 Kaseinavledede peptider og terapeutiske anvendelser derav NO20064388L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54840104P 2004-03-01 2004-03-01
PCT/IL2005/000211 WO2005081628A2 (en) 2004-03-01 2005-02-20 Casein derived peptides and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
NO20064388L true NO20064388L (no) 2006-11-28

Family

ID=34910999

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064388A NO20064388L (no) 2004-03-01 2006-09-28 Kaseinavledede peptider og terapeutiske anvendelser derav

Country Status (13)

Country Link
US (1) US20070203060A1 (no)
EP (1) EP1751179A4 (no)
JP (1) JP2008509073A (no)
KR (1) KR20070007128A (no)
CN (1) CN101124261A (no)
AU (1) AU2005215943A1 (no)
BR (1) BRPI0507822A (no)
CA (1) CA2558155A1 (no)
EA (1) EA200601575A1 (no)
MX (1) MXPA06010014A (no)
NO (1) NO20064388L (no)
WO (1) WO2005081628A2 (no)
ZA (1) ZA200607735B (no)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1956994B (zh) * 2004-03-31 2012-09-05 特许技术开发株式会社 上皮系细胞增殖促进剂
EP1831361B1 (en) 2004-12-23 2012-01-25 Campina Nederland Holding B.V. Protein hydrolysate enriched in peptides inhibiting dpp-iv and their use
WO2006089921A1 (en) * 2005-02-24 2006-08-31 Dsm Ip Assets B.V. Blood pressure lowering peptides from glycomacropeptide
EA016039B1 (ru) 2005-05-02 2012-01-30 Милеутис Лтд. Способы ухода за лактирующими животными и фармацевтические композиции, используемые для их осуществления
PL2236608T3 (pl) * 2005-10-04 2017-06-30 Soligenix, Inc. Nowe peptydy do leczenia i profilaktyki zaburzeń immuno-zależnych w tym do leczenia i profilaktyki zakażenia przez modulację odporności wrodzonej
WO2007057872A2 (en) * 2005-11-21 2007-05-24 Teagasc-National Diary Products Research Centre Casein-derived antimicrobial peptides and lactobacillus strains that produce them
JP2009517464A (ja) 2005-11-30 2009-04-30 カンピーナ ネーダーランド ホールディング ビー．ブイ． グルカゴン様ペプチド１の活性を増強するタンパク質加水分解物の使用
US7989160B2 (en) 2006-02-13 2011-08-02 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
JP2007254449A (ja) * 2006-02-22 2007-10-04 Snow Brand Milk Prod Co Ltd 脂質改善剤
JP5177778B2 (ja) * 2006-02-24 2013-04-10 雪印メグミルク株式会社 ペプチド
GB2436328A (en) * 2006-03-22 2007-09-26 Regen Therapeutics Plc Peptide derived from colostrinin
CA2649003A1 (en) * 2006-04-11 2007-10-18 Mileutis Ltd. Livestock management for improved reproductive efficiency
WO2007125946A1 (ja) * 2006-04-28 2007-11-08 Snow Brand Milk Products Co., Ltd. ペプチド
DK2032701T3 (da) 2006-06-23 2014-02-10 Alethia Biotherapeutics Inc Polynukleotider og polypeptider, der er inddraget i cancer
JP5188731B2 (ja) * 2007-03-02 2013-04-24 雪印メグミルク株式会社 ペプチド
WO2009138762A2 (en) * 2008-05-15 2009-11-19 Regen Therapeutics Plc Therapeutic use of peptides
NZ571856A (en) * 2008-10-09 2011-02-25 Fonterra Corporate Res And Dev Ltd Use of a phospholipid and ganglioside composition for the treatment or prevention of gout
MX336869B (es) 2008-11-03 2016-02-04 Alethia Biotherapeutics Inc Anticuerpos que bloquean espicificamente la actividad biologica de un antigeno de tumor.
EP2370088B1 (en) 2008-12-27 2016-08-24 Pawan Saharan Mammalian colostrum derived nanopeptides for broadspectrum viral and recurrent infections with a method of isolation thereof
PL2413952T3 (pl) 2009-04-03 2017-08-31 Nestec S.A. Polepszenie promowania zdrowego doganiania wzrostu
WO2010144968A1 (en) * 2009-06-19 2010-12-23 Oral Health Australia Pty Ltd Casein derived protease inhibitory peptides
WO2011050471A1 (en) * 2009-10-28 2011-05-05 University Of Manitoba Yellow pea seed protein-derived peptides
JP5479884B2 (ja) * 2009-12-28 2014-04-23 カルピス株式会社 脳機能改善用組成物および脳機能を改善する方法
CA2797658C (en) 2010-04-21 2021-06-08 Mileutis Ltd. Casein peptide for use in the treatment of uterine infections
PT105073A (pt) * 2010-04-26 2011-10-26 Consejo Superior Investigacion Processo de obtenção de extractos peptídicos bioactivos através da hidrólise de proteínas de soro de leite com enzimas de cynara cardunculus, referidos extractos e respectivas utilizações
HUE045943T2 (hu) 2011-03-31 2020-02-28 Adc Therapeutics Sa Veseasszociált antigén 1 és antigénkötõ fragmensei elleni antitestek
US8865155B2 (en) * 2011-09-29 2014-10-21 Centro De Investigacion En Alimentacion Y Desarrollo, A.C. (Ciad) Lactococcus lactis strains, and bacterial preparations thereof, for the production of bioactive peptides having anti-hypertensive and cholesterol-lowering effects in mammals; nutritional and therapeutic products produced therefrom
AU2013209234B2 (en) 2012-01-09 2017-11-09 Adc Therapeutics Sa Method for treating breast cancer
WO2013133032A1 (ja) * 2012-03-09 2013-09-12 森永乳業株式会社 ジペプチジルペプチダーゼ－ｉｖ阻害剤
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
CN102964427B (zh) * 2012-12-12 2014-01-15 上海交通大学 一种生物活性多肽qepvl及其制备和应用
CN103012552B (zh) * 2012-12-12 2014-03-12 上海交通大学 一种生物活性多肽qepv及其制备和应用
US9352020B2 (en) 2013-03-15 2016-05-31 Mead Johnson Nutrition Company Reducing proinflammatory response
US9289461B2 (en) 2013-03-15 2016-03-22 Mead Johnson Nutrition Company Reducing the risk of autoimmune disease
US9345741B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
US10251928B2 (en) * 2014-11-06 2019-04-09 Mead Johnson Nutrition Company Nutritional supplements containing a peptide component and uses thereof
US9138455B2 (en) 2013-03-15 2015-09-22 Mead Johnson Nutrition Company Activating adiponectin by casein hydrolysate
US9345727B2 (en) * 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component and uses thereof
US8889633B2 (en) 2013-03-15 2014-11-18 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
US11215615B2 (en) * 2014-04-03 2022-01-04 AllerGenis LLC Peptides, reagents and methods for detecting food allergy
CN104697830B (zh) * 2015-02-10 2018-06-15 深圳市新产业生物医学工程股份有限公司 用于hiv检测的酸性处理剂、样本预处理方法、试剂盒及检测方法
WO2016208641A1 (ja) * 2015-06-22 2016-12-29 株式会社明治 血中ヘモグロビン増加用組成物
AU2018227125A1 (en) * 2017-03-03 2019-10-24 Morinaga Milk Industry Co., Ltd. GLP-1 secretagogue and composition
CN107188949B (zh) * 2017-07-06 2019-12-24 浙江辉肽生命健康科技有限公司 一种生物活性多肽eintvqvtst及其制备方法和应用
CN107176995B (zh) * 2017-07-06 2019-12-24 浙江辉肽生命健康科技有限公司 一种生物活性多肽skvlpvpekavpypq及其制备方法和应用
AU2018332486B2 (en) * 2017-09-15 2022-06-02 Kine Sciences Co., Ltd. Use of peptides as therapeutic agent for autoimmune diseases and bone diseases
CN107903314A (zh) * 2017-11-14 2018-04-13 上海交通大学 一种生物活性多肽eviesppeintv及其制备方法和应用
TWI655203B (zh) * 2017-11-16 2019-04-01 國立中興大學 新穎胜肽、含有該胜肽之組合物及其用途
CN107814835B (zh) * 2017-12-01 2020-04-28 熊猫乳品集团股份有限公司 一种生物活性多肽avpitptlnreq及其制备方法和应用
CN107827971B (zh) * 2017-12-07 2020-04-14 浙江辉肽生命健康科技有限公司 一种生物活性多肽qsltltdve及其制备方法和应用
CN107880102A (zh) * 2017-12-07 2018-04-06 浙江辉肽生命健康科技有限公司 一种生物活性多肽peviesppein及其制备方法和应用
CN107759682B (zh) * 2017-12-07 2021-03-02 浙江辉肽生命健康科技有限公司 一种生物活性多肽pigsensgkttmpl及其制备方法和应用
CN107814839A (zh) * 2017-12-07 2018-03-20 浙江辉肽生命健康科技有限公司 一种生物活性多肽pigsensekttmpl及其制备方法和应用
CN108017703B (zh) * 2017-12-11 2020-07-17 浙江辉肽生命健康科技有限公司 一种生物活性多肽vpitptln及其制备方法和应用
CN107827972A (zh) * 2017-12-11 2018-03-23 浙江辉肽生命健康科技有限公司 一种生物活性多肽speviesppein及其制备方法和应用
CN107880106B (zh) * 2017-12-11 2020-06-16 浙江辉肽生命健康科技有限公司 一种生物活性多肽vpitptlnre及其制备方法和应用
CN107880104A (zh) * 2017-12-11 2018-04-06 浙江辉肽生命健康科技有限公司 一种生物活性多肽sppeintvqvt及其制备方法和应用
CN107880105B (zh) * 2017-12-11 2020-06-16 浙江辉肽生命健康科技有限公司 一种生物活性多肽vpitptlnr及其制备方法和应用
CN108017708A (zh) * 2017-12-12 2018-05-11 浙江辉肽生命健康科技有限公司 一种生物活性多肽npigsensekttmpl及其制备方法和应用
CN107880108A (zh) * 2017-12-12 2018-04-06 浙江辉肽生命健康科技有限公司 一种生物活性多肽sfsdipnpigse及其制备方法和应用
CN108017709B (zh) * 2017-12-12 2020-04-10 浙江辉肽生命健康科技有限公司 一种生物活性多肽kepmigvnqela及其制备方法和应用
CN107814840B (zh) * 2017-12-12 2020-04-10 浙江辉肽生命健康科技有限公司 一种生物活性多肽pkypvepf及其制备方法和应用
CN108034002A (zh) * 2017-12-12 2018-05-15 浙江辉肽生命健康科技有限公司 一种生物活性多肽peviesppeintv及其制备方法和应用
KR102073824B1 (ko) * 2018-04-11 2020-02-05 강원대학교산학협력단 간 보호용 건강기능식품 및 이의 제조 방법
CA3223596A1 (en) * 2021-06-29 2023-01-05 Thomas A. GILL Peptides for regulating glucose
CN113952446B (zh) * 2021-09-03 2023-12-05 河南省医药科学研究院 生物活性肽在抑制骨髓毒性中的应用
CN116333151B (zh) * 2022-08-12 2023-08-25 广西壮族自治区水牛研究所 一种用于检测水牛奶中掺假普通牛乳的单克隆抗体及其制备方法和用途
CN117567586A (zh) * 2023-10-25 2024-02-20 广州菲勒生物科技有限公司 一种富含唾液酸化肽的水解酪蛋白的制备方法及其在调节肠道菌群中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968901A (en) * 1989-10-30 1999-10-19 Andersson; Bengt Antibacterial composition
US5707968A (en) * 1994-05-26 1998-01-13 Abbott Laboratories Inhibition of attachment of H.influenzae to human cells
IL134830A0 (en) * 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
TWI268138B (en) * 2000-05-11 2006-12-11 Kanebo Seiyaku Ltd Composition containing peptide and electrolyte excretion enhancing substance, and food containing the same
IL160548A0 (en) * 2001-08-30 2004-07-25 Chay 13 Medical Res Group N V Casein derived peptides and uses thereof in therapy

Also Published As

Publication number Publication date
US20070203060A1 (en) 2007-08-30
WO2005081628A2 (en) 2005-09-09
MXPA06010014A (es) 2007-03-07
BRPI0507822A (pt) 2007-07-10
EP1751179A4 (en) 2009-03-25
JP2008509073A (ja) 2008-03-27
CA2558155A1 (en) 2005-09-09
AU2005215943A1 (en) 2005-09-09
WO2005081628A3 (en) 2007-10-18
KR20070007128A (ko) 2007-01-12
CN101124261A (zh) 2008-02-13
ZA200607735B (en) 2008-05-28
EA200601575A1 (ru) 2007-06-29
EP1751179A2 (en) 2007-02-14

Similar Documents

Publication Publication Date Title
NO20064388L (no) Kaseinavledede peptider og terapeutiske anvendelser derav
DK1261360T3 (da) Casein-afledte peptider og anvendelser deraf i behandling
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
UA99094C2 (ru) Способ лечения пациента с системной красной волчанкой
WO2006066008A3 (en) Device and methods for identifying and treating aspirin non-responsive patients
EA200971053A1 (ru) Способы лечения кожных язв
ATE476983T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege
NO20060483L (no) VEGF-feller og terapeutiske anvendelser derav
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
NO20070372L (no) Amidoforbindelser og anvendelse derav som farmasoytiske preparater
DE602007013618D1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
CA2821268C (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
MX2011013296A (es) Metodos de tratamiento o prevención de enfermedad asociada a influenza con soluciones acuosas con potencial de oxidación-reduccion.
WO2005077462A3 (en) Cd70 inhibition for the treatment and prevention of inflammatory bowel disease
NO20055474L (no) Mediatorer av revers kolesteroltransport for behandling av hyperkolesterolemi
MA34547B1 (fr) Traitement d'association pour traiter une infection par le vhc
WO2009023333A3 (en) Inhibition of the sh2-domain containing protein tyr-phosphatase, shp-1, to enhance vaccines
WO2005123119A3 (en) Administration of neutral endopeptidase to treat inflammatory bowel disease
ATE537249T1 (de) Wiedergewinnung von gewebefunktion nach verabreichung von b-zellen an verletztes gewebe
NO20076405L (no) Anvendelse av 24-nor-UDCA
NO20071706L (no) Koadministrering av Tigecycline og Digoxin.
WO2007036735A3 (en) Immunogenic agents againts burkholderia psudomallei and/or burkholderia mallei, comprising lipopolysaccharide, capsular polysaccharide and/or proteins from burkholderia psuedomallei
ATE382383T1 (de) Apherese-vorrichtung
WO2004066942A3 (en) Purification and uses of dendritic cells and monocytes
NO20060637L (no) Autologe selv-toleranse induserende celler av monocytisk opprinnelse og deres anvendelse i farmasoytiske preparater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application